Newsletter

*|MC:SUBJECT|*
View this email in your browser
LAST NEWS ABOUT THE CLINICAL TRIAL
Patients about to finish the clinical trial

This autumn the clinical trial will finish in all the centres involved. Up to now, 53* patients have already finished their participation. After that, the MyCyFAPP team will be able to analyze the result and assess the impact that using the self-management APP has had on the patients’ general wellbeing and on their quality of life. 

The Consortium will publish its conclusions and will start the complex process for making the APP available after the trial.   

In the last stage of the Project, we want to thank all the patients that have made it possible. We are very grateful to all those patients and families who have been using the APP for six months during the clinical trial, giving us a very valuable feedback. Also, special thanks to those patients from Germany and Norway who contributed with their views on the first step of the Project in order to make possible a friendly app.

*data as of 7th September 2018

Why was faeces collection a must for MyCyFAPP clinical trial
The protocol designed for the clinical trial included a stool collection that will allow the Consortium to analyze the percentage of fat absorbed by the organism of each individual. In this way, it can be determined the efficacy of the new model for the calculation of the Pancreatic Enzyme Replacement Therapy suggested by the algorithm in the self-management APP.  

At the beginning of the clinical trial, patients were asked to do a stool collection after 24-hours of free diet taking the amount of Pancreatic Enzyme doses they usually take. After one month of using the APP, the patients followed the same 24 hours diet but, this time, they took the amount of PERT dose suggested by the self-management APP. 

In total, 167 samples from 87 patients have been studied. This stool collection represents also a big step in the research of nutrition in cystic fibrosis as is the first time that a multicentric and international study stool collection.  

In addition to the fat absorption, the laboratory has also analysed the calprotectin, a biological marker used to detect inflammation in the intestines, and the PH.

This task represents an enormous work of coordination and collaboration from all the clinical partners involved as all the stool samples have been stored, treated and analysed at the Paediatric Gastroenterology and Celiac Disease research laboratory from the Instituto de Investigación Sanitaria La Fe (Valencia, Spain). 

The protocol designed for the clinical trial included a stool collection that will allow the Consortium to analyze the percentage of fat absorbed by the organism of each individual. In this way, it can be determined the efficacy of the new model for the calculation of the Pancreatic Enzyme Replacement Therapy suggested by the algorithm in the self-management APP.  

At the beginning of the clinical trial, patients were asked to do a stool collection after 24-hours of free diet taking the amount of Pancreatic Enzyme doses they usually take. After one month of using the APP, the patients followed the same 24 hours diet but, this time, they took the amount of PERT dose suggested by the self-management APP. 

In total, 167 samples from 87 patients have been studied. This stool collection represents also a big step in the research of nutrition in cystic fibrosis as is the first time that a multicentric and international study stool collection.  

In addition to the fat absorption, the laboratory has also analysed the calprotectin, a biological marker used to detect inflammation in the intestines, and the PH.

This task represents an enormous work of coordination and collaboration from all the clinical partners involved as all the stool samples have been stored, treated and analysed at the Paediatric Gastroenterology and Celiac Disease research laboratory from the Instituto de Investigación Sanitaria La Fe (Valencia, Spain). 

MYCYFAPP LAST SCIENTIFIC PUBLICATION
Journal of Food Science has published a new paper about MyCyFAPP. In Vitro Digestion of Lipids in Real Foods: Influence of Lipid Organization within the Food Matrix and Interactions with Nonlipid Components.​
Read more
PHD JOAQUIM CALVO-LERMA

Joaquim Calvo defended its doctoral thesis: “Study of fat digestion in foods as an innovative approach to adjust pancreatic enzyme replacement therapy in Cystic Fibrosis”. 

Calvo was awarded with a distinction Cum Laude and the PhD thesis is proposed for the Extraordinay Doctoral Award at Universitat Politècnica de València. Congratulations!

UPCOMING EVENTS
  • XPatient Barcelona. Read more. Next 20th September. Hands-on exhibition.
  • European Research Night. 28th September at the Instituto de Investigación Sanitaria La Fe. Read more.
  • 9th South-Eastern European Cystic Fibrosis Conference. Next 17th October MyCyFAPP will be presented at the 9th South Eastern European CF Conference. Read more
  • ICT 2018. MYCYFAPP participates in this research and innovation event that focuses on the European Union's priorities in the digital transformation of society and industry.  More information coming up in the following weeks.
What is in vitro digestion?

One of the major innovations of MyCyFAPP are the in vitro digestion studies. For this reason, the Dissemination Team, together with the IIAD team have recorded a video explaining step by step how the in vitro digestion studies have been performed.

MyCyFAPP in the media
Hospital La Fe participates in the clinical trial of an innovative app for improving the quality of life of children with cystic fibrosis. 
Children from the Hospital La Fe (Valencia, Spain) participate in a multicentric clinical trial.
MyCyFAPP in an image
Visit our Download area on the website to learn more about the project. New brochure and leaflet available. 
MYCYFAPP CONSORTIUM
Multidisciplinary research team, integrated by nutritionists/dieticians, paediatric gastroenterologists and pulmonologists, food technologists, food engineers, informatics, psychologists and experts specialised in new technologies areas of knowledge and experts.
Copyright © *|2018_YEAR|* *|LIST:MYCYFAPP NEWSLETTER|*, All rights reserved.
*|LIST:NEWSLETTER|*

Our mailing address is:
*|INFO@MYCYFAPP.EU* 

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.






This email was sent to *|EMAIL|*
why did I get this?    unsubscribe from this list    update subscription preferences
*|LIST:ADDRESSLINE|*

*|REWARDS|*

Subscribe to our mailing list

* indicates required

Privacy pokicy

You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at info@mycyfapp.eu. We will treat your information with respect. For more information about our privacy practices please visit our website. By clicking "suscribe", you agree that we may process your information in accordance with these terms.

We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.

logo DEFINITIVO copy

euflagProject funded by the European Union
under the Grant Agreement number 643806

logoehealth

MyCyFAPP is a project funded by the European Commission under the Research and Innovation Framework Programme “Horizon 2020”